These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 35972551)

  • 1. Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters.
    Morell A; Budagaga Y; Vagiannis D; Zhang Y; Laštovičková L; Novotná E; Haddad A; Haddad M; Portillo R; Hofman J; Wsól V
    Arch Toxicol; 2022 Dec; 96(12):3265-3277. PubMed ID: 35972551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters.
    Sorf A; Novotna E; Hofman J; Morell A; Staud F; Wsol V; Ceckova M
    Biochem Pharmacol; 2019 May; 163():290-298. PubMed ID: 30826329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bruton's Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux.
    Čermáková L; Hofman J; Laštovičková L; Havlíčková L; Špringrová I; Novotná E; Wsól V
    Pharmaceutics; 2022 Sep; 14(10):. PubMed ID: 36297430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective inhibition of aldo-keto reductase 1C3: a novel mechanism involved in midostaurin and daunorubicin synergism.
    Morell A; Novotná E; Milan J; Danielisová P; Büküm N; Wsól V
    Arch Toxicol; 2021 Jan; 95(1):67-78. PubMed ID: 33025066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
    Hofman J; Malcekova B; Skarka A; Novotna E; Wsol V
    Toxicol Appl Pharmacol; 2014 Aug; 278(3):238-48. PubMed ID: 24832494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions of antileukemic drugs with daunorubicin reductases: could reductases affect the clinical efficacy of daunorubicin chemoregimens?
    Novotná E; Morell A; Büküm N; Hofman J; Danielisová P; Wsól V
    Arch Toxicol; 2020 Sep; 94(9):3059-3068. PubMed ID: 32588086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Transporter-Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients With Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Cheng Y; Wang X; Tong Z; Reyes J; Carayannopoulos L; Zhou S; Li Y
    J Clin Pharmacol; 2022 Apr; 62(4):494-504. PubMed ID: 34617279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C3.
    Tavares TS; Hofman J; Lekešová A; Želazková J; Wsól V
    Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33114555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells.
    Kim Y; Jeung HK; Cheong JW; Song J; Bae SH; Lee JI; Min YH
    Yonsei Med J; 2020 Sep; 61(9):762-773. PubMed ID: 32882760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia.
    Dogra R; Bhatia R; Shankar R; Bansal P; Rawal RK
    Anticancer Agents Med Chem; 2018; 18(14):1936-1951. PubMed ID: 30360730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.
    Fathi AT; DiNardo CD; Kline I; Kenvin L; Gupta I; Attar EC; Stein EM; de Botton S;
    JAMA Oncol; 2018 Aug; 4(8):1106-1110. PubMed ID: 29346478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent and Highly Selective Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
    Verma K; Zang T; Penning TM; Trippier PC
    J Med Chem; 2019 Apr; 62(7):3590-3616. PubMed ID: 30836001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enasidenib in mutant
    Stein EM; DiNardo CD; Pollyea DA; Fathi AT; Roboz GJ; Altman JK; Stone RM; DeAngelo DJ; Levine RL; Flinn IW; Kantarjian HM; Collins R; Patel MR; Frankel AE; Stein A; Sekeres MA; Swords RT; Medeiros BC; Willekens C; Vyas P; Tosolini A; Xu Q; Knight RD; Yen KE; Agresta S; de Botton S; Tallman MS
    Blood; 2017 Aug; 130(6):722-731. PubMed ID: 28588020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
    DiNardo CD; Schuh AC; Stein EM; Montesinos P; Wei AH; de Botton S; Zeidan AM; Fathi AT; Kantarjian HM; Bennett JM; Frattini MG; Martin-Regueira P; Lersch F; Gong J; Hasan M; Vyas P; Döhner H
    Lancet Oncol; 2021 Nov; 22(11):1597-1608. PubMed ID: 34672961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
    de Botton S; Montesinos P; Schuh AC; Papayannidis C; Vyas P; Wei AH; Ommen H; Semochkin S; Kim HJ; Larson RA; Koprivnikar J; Frankfurt O; Thol F; Chromik J; Byrne J; Pigneux A; Thomas X; Salamero O; Vidriales MB; Doronin V; Döhner H; Fathi AT; Laille E; Yu X; Hasan M; Martin-Regueira P; DiNardo CD
    Blood; 2023 Jan; 141(2):156-167. PubMed ID: 35714312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Silico and In Vitro Assessment of Carbonyl Reductase 1 Inhibition Using ASP9521-A Potent Aldo-Keto Reductase 1C3 Inhibitor with the Potential to Support Anticancer Therapy Using Anthracycline Antibiotics.
    Jamrozik M; Piska K; Bucki A; Koczurkiewicz-Adamczyk P; Sapa M; Władyka B; Pękala E; Kołaczkowski M
    Molecules; 2023 Apr; 28(9):. PubMed ID: 37175180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment.
    Novotná E; Büküm N; Hofman J; Flaxová M; Kouklíková E; Louvarová D; Wsól V
    Biochem Pharmacol; 2018 Oct; 156():22-31. PubMed ID: 30077642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2-Mutant Acute Myeloid Leukemia.
    Fan B; Chen Y; Yin F; Hua L; Almon C; Nabhan S; Cooper M; Yang H; Hossain M
    Clin Pharmacol Drug Dev; 2022 Apr; 11(4):429-441. PubMed ID: 35166065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enasidenib for the treatment of acute myeloid leukemia.
    Dugan J; Pollyea D
    Expert Rev Clin Pharmacol; 2018 Aug; 11(8):755-760. PubMed ID: 29770715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3.
    Bukum N; Novotna E; Morell A; Hofman J; Wsol V
    Chem Biol Interact; 2019 Apr; 302():101-107. PubMed ID: 30703376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.